| Literature DB >> 25669219 |
Yoon-Hyeong Choi1, Jin Hee Kim2, Yun-Chul Hong3.
Abstract
BACKGROUND: The prevalence of metabolic diseases rises rapidly with an ageing population. Recent studies suggest the potential involvement of environmental chemicals in insulin resistance (IR) that plays a core role in the development of metabolic diseases. Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous components of outdoor and indoor air pollution. The influence of PAHs on IR may differ depending on sex and weight.Entities:
Keywords: Biomonitoring; ELDERLY; Environmental epidemiology
Mesh:
Substances:
Year: 2015 PMID: 25669219 PMCID: PMC4484041 DOI: 10.1136/jech-2014-204801
Source DB: PubMed Journal: J Epidemiol Community Health ISSN: 0143-005X Impact factor: 3.710
General characteristics (mean±SD) at enrolment (n=502)
| Characteristic | All (n=502) | Male (n=132) | Female (n=370) | p Value* |
|---|---|---|---|---|
| Number of visits | 1.7±0.5 | 1.6±0.5 | 1.7±1.5 | 0.104 |
| Age (years) | 70.8±5.3 | 71.3±4.5 | 70.6±5.5 | 0.126 |
| BMI (kg/m2) | 24.8±2.9 | 24.3±3.2 | 24.9±2.9 | 0.038 |
| Fasting insulin (µU/mL) | 7.0±6.0 | 6.1±4.5 | 7.3±6.4 | 0.018 |
| Fasting glucose (mmol/L) | 5.34±1.15 | 5.4±1.2 | 5.3±1.2 | 0.529 |
| HOMA-IR† | 1.7±1.7 | 1.5±1.3 | 1.8±1.8 | 0.059 |
| Urinary PAH, 1-OHP (µg/g Cr)‡ | 0.12 (0.11 to 0.13) | 0.11 (0.09 to 0.13) | 0.12 (0.11 to 0.14) | 0.234 |
| Urinary cotinine (µg/g Cr)‡ | 3.23 (2.69 to 3.86) | 8.79 (5.20 to 14.84) | 2.26 (1.96 to 2.60) | <0.001 |
| Ambient PM10 (µg/m3 on lag day 1) | 44.4±25.1 | 39.2±21.5 | 46.3±26.1 | 0.005 |
| Education (n (%)) | <0.001 | |||
| ≤Elementary School | 284 (56.6) | 37 (28.0) | 247 (66.8) | |
| ≤High School | 164 (32.7) | 57 (43.2) | 107 (28.9) | |
| >High School | 54 (10.8) | 38 (28.8) | 16 (4.3) | |
| Physical activity (moderate to vigorous leisure; n (%)) | 313 (62.4) | 82 (62.1) | 231 (62.4) | 1.000 |
| Current hypertension (n (%)) | 334 (66.5) | 92 (69.7) | 242 (65.4) | 0.392 |
| Current diabetes mellitus (n (%)) | 168 (33.5) | 50 (37.9) | 118 (31.9) | 0.237 |
| Low HDL-C§ (n (%)) | 199 (39.6) | 34 (25.8) | 165 (44.6) | <0.001 |
*Continuous variables: t test; categorical variables: 2×2 table (Fisher’s exact test) or 2×C table (Mantel-Haenszel χ2 test).
†HOMA index: fasting insulin (µU/mL) × fasting glucose (mmol/L)/22.5.
‡Geometric means (95% CI) were presented.
§Male: HDL-C <40 mg/dL; female: HDL-C <50 mg/dL.
BMI, body mass index; Cr, creatinine; HDL-C, high-density lipoprotein cholesterol; HOMA, homoeostatic model assessment; IR, insulin resistance; PAH, polycyclic aromatic hydrocarbons; PM10, particulate matter ≤10 μm in diameter.
Characteristics of study population by urinary 1-OHP quartile
| 1-OHP metabolite (µg/g Cr) (n=502) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q1(0.0011–0.075) | Q2(0.075–0.124) | Q3(0.124–0.203) | Q4(0.204–4.461) | p Trend | |||||
| Number of participants (n (%)) | |||||||||
| All | 125 | 126 | 126 | 125 | |||||
| Male | 40 | (32.0) | 37 | (29.4) | 27 | (21.4) | 28 | (22.4) | |
| Female | 85 | (68.0) | 89 | (70.6) | 99 | (78.6) | 97 | (77.6) | |
| Glucose (mmol/L) | |||||||||
| All | 5.27 | (±1.03) | 5.37 | (±1.06) | 5.19 | (±0.71) | 5.54 | (±1.60) | 0.183 |
| Male | 5.32 | (±1.13) | 5.59 | (±1.25) | 5.10 | (±0.64) | 5.54 | (±1.39) | 0.842 |
| Female | 5.25 | (±0.98) | 5.28 | (±0.96) | 5.22 | (±0.73) | 5.54 | (±1.67) | 0.131 |
| Insulin (µU/mL) | |||||||||
| All | 6.58 | (±4.97) | 6.61 | (±5.04) | 7.11 | (±5.97) | 7.59 | (±7.71) | 0.143 |
| Male | 6.36 | (±5.19) | 6.22 | (±4.59) | 6.00 | (±4.79) | 5.50 | (±3.07) | 0.436 |
| Female | 6.68 | (±4.88) | 6.78 | (±5.24) | 7.41 | (±6.24) | 8.19 | (±8.51) | 0.084 |
| HOMA-IR (score)* | |||||||||
| All | 1.60 | (±1.42) | 1.61 | (±1.28) | 1.71 | (±1.62) | 1.98 | (±2.36) | 0.068 |
| Male | 1.57 | (±1.49) | 1.57 | (±1.25) | 1.45 | (±1.38) | 1.43 | (±1.10) | 0.601 |
| Female | 1.61 | (±1.40) | 1.62 | (±1.30) | 1.79 | (±1.68) | 2.14 | (±2.60) | 0.039 |
*HOMA index: fasting insulin (µU/mL) × fasting glucose (mmol/L)/22.5.
1-OHP, 1-hydroxypyrene; Cr, creatinine; HOMA, homoeostatic model assessment; IR, insulin resistance.
Regression coefficients (β (95% CIs)) for change in glucose, insulin and HOMA-IR score by a unit increase in ln-transformed urinary 1-OHP
| 1-OHP (ln)a | Glucose (mmol/L) | p Value | Insulin (µU/mL) | p Value | HOMA-IR | ||||
|---|---|---|---|---|---|---|---|---|---|
| β | (95% CIs) | β | (95% CIs) | β | (95% CIs) | p Value | |||
| Model A | 0.03 | (−0.03, 0.10) | 0.332 | 0.34 | (−0.13, 0.81) | 0.154 | 0.14 | (−0.01, 0.30) | 0.077 |
| Model B | 0.03 | (−0.03, 0.10) | 0.332 | 0.33 | (−0.13, 0.80) | 0.164 | 0.14 | (−0.02, 0.30) | 0.079 |
| Model C | 0.03 | (−0.03, 0.10) | 0.290 | 0.38 | (−0.09, 0.84) | 0.117 | 0.16 | (0.00, 0.31) | 0.052 |
| Model D | 0.04 | (−0.02, 0.10) | 0.160 | 0.36 | (−0.10, 0.82) | 0.130 | 0.16 | (0.00, 0.31) | 0.049 |
| Model E | 0.03 | (−0.03, 0.10) | 0.336 | 0.34 | (−0.12, 0.80) | 0.152 | 0.15 | (−0.01, 0.30) | 0.069 |
Model A was adjusted for age, sex and elapsed time since the first visit.
Model B: Model A+further adjusted for education and physical activity.
Model C: Model B+further adjusted for urinary cotinine and ambient PM10 concentrations.
Model D: Model C+further adjusted for obesity, diabetes, hypertension and HDL-cholesterol.
Model E: Model D—deductible adjustment for diabetes.
Change in glucose, insulin and HOMA for 1 unit ln-1-OHP increase.
1-OHP, 1-hydroxypyrene; HDL, high-density lipoprotein; HOMA, homoeostatic model assessment; IR, insulin resistance; PM10, particulate matter ≤10 μm in diameter.
Figure 1Fully-adjusted changes (95% CI) in HOMA-IR score in relation to 1-OHP quartiles (quartile 1 is reference) in (A) overall participants, (B) different sex, and in subgroups stratified by overweight in (C) men and (D) women. Values were adjusted for age, sex, elapsed time, education, physical activities, BMI, hypertension, HDL-cholesterol, cotinine, and ambient PM10. Overweight was defined as BMI≥25kg/m2. 1-OHP quartiles cut-off points: 0.0753, 0.1237, 0.203 µg/g Cr” BMI, body mass index; 1-OHP, 1-hydroxypyrene; HOMA-IR, homoeostatic model assessment of insulin resistance)